PMC:7461420 / 15064-15332 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T85","span":{"begin":69,"end":76},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma82753"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T89","span":{"begin":182,"end":186},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T155","span":{"begin":14,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T156","span":{"begin":96,"end":103},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T157","span":{"begin":104,"end":106},"obj":"http://purl.obolibrary.org/obo/CLO_0008337"},{"id":"T158","span":{"begin":117,"end":119},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T159","span":{"begin":145,"end":152},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T160","span":{"begin":163,"end":166},"obj":"http://purl.obolibrary.org/obo/CLO_0001310"},{"id":"T161","span":{"begin":180,"end":181},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T96","span":{"begin":4,"end":13},"obj":"Chemical"},{"id":"T97","span":{"begin":69,"end":76},"obj":"Chemical"},{"id":"T100","span":{"begin":96,"end":103},"obj":"Chemical"},{"id":"T101","span":{"begin":104,"end":106},"obj":"Chemical"},{"id":"T102","span":{"begin":145,"end":152},"obj":"Chemical"}],"attributes":[{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_15428"},{"id":"A98","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_29947"},{"id":"A99","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_57305"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_35895"},{"id":"A102","pred":"chebi_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}

{"project":"LitCovid-PubTator","denotations":[{"id":"501","span":{"begin":132,"end":136},"obj":"Gene"},{"id":"505","span":{"begin":182,"end":190},"obj":"Species"},{"id":"509","span":{"begin":69,"end":76},"obj":"Chemical"},{"id":"511","span":{"begin":242,"end":254},"obj":"Disease"}],"attributes":[{"id":"A501","pred":"tao:has_database_id","subj":"501","obj":"Gene:59272"},{"id":"A505","pred":"tao:has_database_id","subj":"505","obj":"Tax:694009"},{"id":"A509","pred":"tao:has_database_id","subj":"509","obj":"MESH:D005998"},{"id":"A511","pred":"tao:has_database_id","subj":"511","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}

{"project":"LitCovid-sentences","denotations":[{"id":"T156","span":{"begin":0,"end":268},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (residues 22–47) with an ACE2‐derived peptide (residues 351–357) against a SARS‐CoV‐1 pseudovirus with an IC50 of 100 nM and devoid of cytotoxicity up to 200 µM."}